Lipid nanoparticle system loaded with water-soluble medicine as well as preparation method and application of lipid nanoparticle system
By constructing a lipid nanoparticle system loaded with water-soluble drugs, the dopamine receptors of olfactory sensory neurons are used for efficient delivery, which solves the problem of poor permeability of hydrophilic compounds in the nasal and brain delivery system, and achieves efficient brain delivery of drugs and enrichment.
Patent Information
- Application Number
- CN202410999435.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-24
AI Technical Summary
The existing nasal and brain delivery system has poor permeability of hydrophilic compounds, which leads to low efficiency in nasal and brain delivery, making it difficult to achieve efficient brain delivery of drugs.
Using a lipid nanoparticle system with water-soluble drugs, using dopamine-modified gelatin, liposomes with water-soluble drugs, bafflomycin A1 and TG enzymes as raw materials, to construct a nasal spray lipid nanoparticle system, using olfactory sense The dopamine receptors of sensory neurons are efficiently delivered, triggering the lysosomal exocytosis effect, and achieving efficient release of the exosome form of the drug into the brain.
It breaks through the defects of poor permeability of hydrophilic compounds and low efficiency of nasal and brain delivery, and achieves efficient delivery and enrichment of water-soluble drugs in the brain, improving the efficiency of nasal and brain delivery.
Smart Images

Figure CN118924703A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical technology, and more specifically, the present invention relates to a lipid nanoparticle system loaded with water-soluble drugs for enhancing drug nose-to-brain delivery, and a preparation method and application thereof. Background Art
[0002] The existence of the blood-brain barrier seriously hinders the brain delivery of drugs, affecting the treatment of brain diseases such as Alzheimer's disease. As an emerging brain delivery method, the "nose-brain pathway" has attracted much attention because it can bypass the blood-brain barrier and avoid the first-pass effect of the liver.
[0003] Most of the existing nose-brain drug delivery systems are in situ gel systems, which effectively retain the drug in the nasal cavity through the viscosity of the gel itself, and then deliver the drug to the brain through transcellular or paracellular pathways. In situ gel systems have the defects of mucociliary clearance, enzymatic degradation and short residence time. More importantly, hydrophilic compounds have poor permeability, resulting in too low efficiency of drug delivery in the nose-brain pathway.
[0004] Therefore, it is very necessary to solve the problems of poor permeability of hydrophilic compounds and low efficiency of nose-brain drug delivery. Summary of the invention
[0005] Based on this, the purpose of the present invention is to provide a lipid nanoparticle system loaded with water-soluble drugs and its preparation method and application. The lipid nanoparticle system is a new nose-brain delivery system, which intends to achieve efficient brain delivery of water-soluble drugs through intracellular transport of olfactory sensory neurons in the nasal cavity.
[0006] The technical solutions for achieving the above-mentioned invention objectives include the following.
[0007] The first aspect of the present invention provides a lipid nanoparticle system loaded with a water-soluble drug, wherein the raw materials for preparing the lipid nanoparticle system include 3-5wt% dopamine-modified gelatin, liposomes loaded with a water-soluble drug, 8-12mM bafilomycin A1 and 8-12mg / mL TG enzyme, wherein the volume ratio of the dopamine-modified gelatin to the liposomes loaded with a water-soluble drug is 1:2.5-3.5, and the volume ratio of the bafilomycin A1 to the TG enzyme is 1:9-11.
[0008] The second aspect of the present invention provides a method for preparing the above-mentioned lipid nanoparticle system loaded with water-soluble drugs, comprising the following steps: adding 8-12 mM bafilomycin A1 to 3-5 wt % dopamine modified gelatin, then adding liposomes loaded with water-soluble drugs and 8-12 mg / mL TG enzyme, and incubating at room temperature for 1.5-2.5 h.
[0009] The third aspect of the present invention provides the use of the above-mentioned lipid nanoparticle system loaded with water-soluble drugs in drug delivery via the nose-brain pathway.
[0010] In the present invention, dopamine-modified gelatin, liposomes loaded with water-soluble drugs, bafilomycin A1 and TG enzyme are used as raw materials, and by controlling the preparation process conditions of the liposomes loaded with water-soluble drugs (including the type of external aqueous phase buffer, the pH difference between the internal and external aqueous phases, the concentration of the hydration medium, the drug-lipid ratio, the incubation time, the incubation temperature, etc.), a nasal spray lipid nanoparticle system with a high drug encapsulation rate is constructed; the nasal spray lipid nanoparticle system can be effectively retained in the olfactory area of the nasal cavity, and is taken up by olfactory sensory neurons that highly express DRD2 through the modification of dopamine, releasing the small molecule inhibitor bafilomycin A1, and then acting on the TRPML3 ion channel to increase the lysosomal pH value, thereby triggering the lysosomal exocytosis effect, and realizing the efficient release of water-soluble compounds into the brain in the form of exosomes.
[0011] The lipid nanoparticle system of the present invention overcomes the defects of poor permeability of hydrophilic compounds and low efficiency of nose-brain drug delivery, and achieves efficient delivery and enrichment of hydrophilic drugs in the brain. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 Schematic diagram of the synthesis of dopamine-modified gelatin in Example 1 of the present invention.
[0013] Figure 2 1 is the H NMR spectrum of dopamine, gelatin and dopamine-modified gelatin in Example 1 of the present invention.
[0014] Figure 3 Schematic diagram of the TG enzyme-catalyzed amido transfer reaction in Example 1 of the present invention.
[0015] Figure 4 Schematic diagram of the preparation of itaconic acid lipid nanoparticle system in Example 1 of the present invention.
[0016] Figure 5 The morphology of the ITA-BGePSL nanocage observed by transmission electron microscopy in Example 2 of the present invention.
[0017] Figure 6 The particle sizes and Zeta potentials of the liposomes (PSL), itaconic acid liposomes (ITA-PSL) and itaconic acid lipid nano-vessels (ITA-BGePSL) in Example 2 of the present invention are shown.
[0018] Figure 7 Schematic diagram of nasal spray administration of itaconic acid lipid nano-tank (ITA-BGePSL) in Example 3 of the present invention.
[0019] Figure 8Comparison of the sprayability (representative pictures, spray coverage, spray area and ellipticity) of the gel (B-Gel), itaconic acid liposomes (ITA-PSL) and itaconic acid lipid nano-tanks (ITA-BGePSL) in Example 3 of the present invention.
[0020] Fig. 9 The graph shows the deposition results of the gel (B-Gel), itaconic acid liposomes (ITA-PSL) and itaconic acid lipid nano-tanks (ITA-BGePSL) in Example 3 of the present invention in the olfactory simulation area.
[0021] Fig.10 In Example 4 of the present invention, the BGePSL nanocarrier is selectively taken up by olfactory neurons under the mediation of dopamine receptor D2. The nanocarrier labeled with DiI and FITC acts on the co-culture system of PC12 and nasal mucosal epithelial basal cells for 2 or 12 hours, and the cell uptake of the nanocarrier is detected by flow cytometry.
[0022] Fig.11 The fluorescence amount of RhB in PC12 cells at different time points after RhB-BGePSL treatment in Example 5 of the present invention.
[0023] Fig.12 It is the fluorescence amount of RhB in PC12 cell exosomes at different time points after RhB-BGePSL treatment in Example 5 of the present invention.
[0024] Fig.13 This is the whole body distribution diagram of DiD-labeled BGel, PSL and BGePSL in BALB / c mice after nasal administration in Example 6 of the present invention.
[0025] Fig.14 This is the fluorescence distribution diagram in the brain of BALB / c mice after nasal administration of DiD-labeled BGel, PSL and BGePSL in Example 6 of the present invention.
[0026] Fig.15 These are the quantitative results of the mean fluorescence intensity in the brain of BALB / c mice after nasal administration of DiD-labeled BGel, PSL and BGePSL in Example 6 of the present invention.
[0027] Fig.16 The quantitative results of total fluorescence intensity in the brain of BALB / c mice after nasal administration of DiD-labeled BGel, PSL and BGePSL in Example 6 of the present invention.
[0028] Fig.17 Quantitative graphs of fluorescence distribution and fluorescence intensity in major organs of BALB / c mice after nasal administration of DiD-labeled BGel, PSL and BGePSL in Example 6 of the present invention. DETAILED DESCRIPTION
[0029] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.
[0030] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those commonly understood by those skilled in the art to which the present invention belongs. The terms used in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used in the present invention includes any and all combinations of one or more of the related listed items.
[0031] The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or conditions recommended by the manufacturers. The various commonly used chemical reagents used in the examples are all commercially available products.
[0032] In the present invention, based on the structural characteristics of olfactory sensory neurons directly connecting the nasal cavity and the olfactory bulb of the brain ("nose-brain pathway"), a nasal spray-type water-soluble compound (such as itaconic acid, mesaconic acid and citraconic acid, etc.) lipid nanoparticle system was constructed. As an exosome converter of water-soluble compounds (such as itaconic acid, mesaconic acid and citraconic acid, etc.), it can effectively release the water-soluble compounds into the brain in the form of exosomes. After nasal spray administration, the lipid nanoparticle system of water-soluble compounds (such as itaconic acid, mesaconic acid and citraconic acid, etc.) can be effectively retained in the olfactory area of the nasal cavity, and then taken up by the olfactory sensory neurons that highly express DRD2 (dopamine D2 receptor) with the help of dopamine modification. The water-soluble compound lipid nanoparticle system after uptake responds to the degradation of tissue proteases in the lysosomes and releases the small molecule inhibitor BafA1 (bafilomycin A1). BafA1 can act on the TRPML3 ion channel, increase the pH value of the lysosome, and then trigger the lysosomal exocytosis effect, thereby realizing the exosome release of water-soluble compounds (such as itaconic acid, mesaconic acid and citraconic acid, etc.) into the brain, and efficiently enriching the drug in the brain. The in vivo water-soluble compound (such as itaconic acid, mesaconic acid and citraconic acid, etc.) exosome converter prepared by the present invention not only solves the problem of difficult nose-brain delivery of water-soluble drugs, but also proposes the design of in vitro exosome agonists, which not only retains the advantages of exosomes as drug delivery carriers, but also avoids the technical difficulties of limited sources, small quantities, high costs and difficult acquisition.
[0033] In some embodiments of the present invention, a lipid nanoparticle system loaded with water-soluble drugs is disclosed, wherein the raw materials for preparing the lipid nanoparticle system include 3-5wt% dopamine-modified gelatin, liposomes loaded with water-soluble drugs, 8-12mM bafilomycin A1 and 8-12mg / mL TG enzyme, the volume ratio of the dopamine-modified gelatin to the liposomes loaded with water-soluble drugs is 1:2.5-3.5, and the volume ratio of the bafilomycin A1 to the TG enzyme is 1:9-11.
[0034] In some of the embodiments, the volume ratio of the dopamine-modified gelatin to the liposome loaded with the water-soluble drug is 1:2.8-3.2, and the volume ratio of the bafilomycin A1 to the TG enzyme is 1:9.5-10.5.
[0035] In some of the embodiments, the liposomes loaded with water-soluble drugs are prepared by the following preparation method: using lecithin, phosphatidylserine and cholesterol as raw materials, and PBS buffer with a pH of 7.4 and an ion concentration of 45 to 55 mM as a medium to prepare blank liposomes; dissolving the water-soluble drug in a glycine-hydrochloric acid buffer with a pH of 3.2 to 4.4, and adding it to the blank liposomes at a drug-lipid ratio of 1:3 to 10, incubating at 37 to 50° C. under magnetic stirring for 4 to 12 minutes, and gently shaking in a cold water bath to cool down, to obtain the liposomes.
[0036] In some embodiments, the ion concentration of the PBS buffer is 49-51 mM.
[0037] In some embodiments, the weight ratio of lecithin to phosphatidylserine is 7-9:1-3, and the weight ratio of lecithin to phosphatidylserine and cholesterol is 3:0.8-1.2; preferably, the weight ratio of lecithin to phosphatidylserine is 7:3 or 8:2, more preferably 7:3.
[0038] In some embodiments, the pH of the glycine-HCl buffer is 3.2-3.4, more preferably 3.3.
[0039] In some embodiments, the drug-to-lipid ratio is 1:9-10, more preferably 1:10.
[0040] In some embodiments, the incubation temperature is 45-50° C., more preferably 50° C.; and / or the incubation time is 4-6 min, more preferably 5 min.
[0041] In some embodiments, the water-soluble drug is itaconic acid, mesaconic acid or citraconic acid.
[0042] In other embodiments of the present invention, a method for preparing the above-mentioned lipid nanoparticle system loaded with water-soluble drugs is disclosed, comprising the following steps: adding 8-12 mM bafilomycin A1 to 3-5 wt % dopamine-modified gelatin, then adding liposomes loaded with water-soluble drugs and 8-12 mg / mL TG enzyme, and incubating at room temperature for 1.5-2.5 h.
[0043] In other embodiments of the present invention, the application of the above-mentioned lipid nanoparticle system loaded with water-soluble drugs in the drug delivery via the nose-brain pathway is disclosed.
[0044] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0045] Example 1 Preparation of itaconic acid lipid nanoparticle system
[0046] The following steps are involved:
[0047] 1. Synthesis and characterization of dopamine-modified gelatin
[0048] Dopamine-modified gelatin was synthesized by coupling reaction under the activation of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS). Figure 1 shown.
[0049] Weigh 2.0g of gelatin and add it to 100mL of PBS (pH 7.4) solution, heat at 60℃ to dissolve. Add 0.5g of EDC and 0.3g of NHS to the above solution, adjust the pH value of the mixed solution to 5.0 with hydrochloric acid, and stir for 30 minutes. Then dissolve 1g of dopamine hydrochloride in 2mL of deionized water, add it to the mixed solution, and keep the pH between 5.0-6.0, and stir at 37℃ in the dark for 24h. Then dialyze the reaction solution in deionized water in the dark for 2 days, and freeze-dry to obtain dopamine-modified gelatin, i.e., Gelatin-dopamine.
[0050] The structures of the reactants and products were determined by nuclear magnetic resonance spectroscopy (1H NMR). Appropriate amounts of gelatin, dopamine, and dopamine-modified gelatin (Gelatin-dopamine) were dissolved in D2O at a frequency of 400 MHz. The structures of the samples were confirmed by nuclear magnetic resonance spectroscopy. The results are as follows: Figure 2 As shown. Figure 2It can be seen that the chemical shift of the methylene group on the benzyl group in dopamine is 2.75ppm (CH2), and a characteristic peak of the methylene group on the benzyl group appears at a chemical shift of 2.75ppm in the H NMR spectrum of dopamine-modified gelatin. Since this characteristic peak does not exist in the H NMR spectrum of gelatin, the methylene peak on the benzyl group in dopamine will appear in the H NMR spectrum of dopamine-modified gelatin only after an amide reaction with dopamine. Therefore, the appearance of this characteristic peak proves the successful synthesis of dopamine-modified gelatin.
[0051] 2. Preparation of phosphatidylserine blank liposomes (PSL)
[0052] Phosphatidylserine blank liposomes (PSL) were prepared by thin film hydration method.
[0053] Weigh a certain amount of lecithin, phosphatidylserine, and cholesterol (mass ratio is 52.5 / 22.5 / 25), dissolve in chloroform solution, remove chloroform by vacuum rotary evaporation at 35℃ for 15min, and obtain a uniform lipid dry film. Add PBS buffer (50mM) with pH 7.4, hydrate at 60℃ for 1h, and obtain a liposome crude dispersion system. The obtained phosphatidylserine blank liposome crude dispersion system is dispersed by ice bath ultrasonic dispersion (7min; on 2s; off 3s) by cell disruptor (probe No. 6; power 30%), and then pass through 0.80μm, 0.45μm and 0.22μm filter membranes in sequence to obtain phosphatidylserine blank liposomes (PSL). The above blank liposomes are dialyzed in deionized water for 1.5h to prepare gradient blank liposomes.
[0054] 3. Preparation of itaconic acid-loaded phosphatidylserine liposomes (ITA-PSL)
[0055] Itaconic acid (ITA) was dissolved in a pH 3.3 glycine-hydrochloric acid buffer and added to the gradient blank liposomes at a drug-lipid ratio of 1:10, and incubated at 50°C for 5 minutes under magnetic stirring. After 5 minutes, the mixture was gently shaken in a cold water bath to cool down, and drug loading was terminated to obtain itaconic acid-loaded phosphatidylserine liposomes (ITA-PSL).
[0056] 4. Preparation of itaconic acid lipid nanoparticle system (ITA-BGePSL)
[0057] Take 0.25mL of 4% dopamine-modified gelatin (Gelatin-dopamine) and add 3μL of 10mM bafilomycin A1 (BafA1). Then add 0.75mL of itaconic acid-loaded phosphatidylserine liposomes (ITA-PSL) and 30μL of 10mg / mL TGase to the above solution, incubate at room temperature for 2h, and use the γ-amide group of the glutamine residue in gelatin and the ε-amino group of lysine to carry out amide transfer reaction ( Figure 3 ), prepare the itaconic acid lipid nanoparticle system loaded with bafilomycin A1 (i.e., ITA-BGePSL, hereinafter referred to as itaconic acid lipid nanoparticle), the preparation schematic diagram is shown in Figure 4 .
[0058] Example 2 Performance of the itaconic acid lipid nanocompartment prepared in Example 1
[0059] 1. Appearance
[0060] Use deionized water instead of PBS buffer, and prepare blank liposome PSL according to the method of step 2 of Example 1 (because some salt crystal precipitation may interfere with shooting and affect the shooting effect when taking pictures under a transmission electron microscope, deionized water is used instead of PBS buffer). Under room temperature, the copper mesh covered with carbon film is inverted on 10 μL of blank liposome PSL and itaconic acid lipid nanocompartment ITA-BGePSL solution, respectively, and the excess sample solution is absorbed with filter paper after standing for 1 min. After the water evaporates, the copper mesh is inverted on 10 μL of 3% phosphotungstic acid staining solution for 20s, and the excess staining solution is absorbed with filter paper. After being left to dry naturally at room temperature, it is observed and photographed with a transmission electron microscope (FEI Tecnai G2 F30).
[0061] The results of transmission electron microscopy observations are as follows Figure 5 As shown, the blank liposome PSL presents a typical phospholipid bilayer structure, while the itaconic acid lipid nanocompartment ITA-BGePSL presents a spherical shape. The particle size distributions of the blank liposome PSL and the itaconic acid lipid nanocompartment ITA-BGePSL are relatively uniform, and their sizes are close to the results of DLS determination.
[0062] 2. Particle size and Zeta potential
[0063] The particle size and zeta potential of PSL (Example 1, step 2), ITA-PSL (Example 1, step 3), and ITA-BGePSL (Example 1, step 4) were measured using a Malvern ZS90 particle size analyzer.
[0064] The changes of particle size and Zeta potential during the preparation of itaconate lipid nanocompartments (ITA-BGePSL) Figure 6As shown. First, ITA-PSL was prepared by pH gradient method as the liposome core of itaconic acid lipid nanocompartment. Compared with liposome PSL, the particle size of ITA-PSL did not change significantly after loading ITA, but the Zeta potential was significantly reduced due to the negative charge of ITA. After BafA1, dopamine-modified gelatin and TGase were further added to ITA-PSL, gelatin underwent amide transfer reaction under the catalysis of TGase to form a gel shell, and then ITA-PSL and BafA1 were wrapped in the gel shell. The particle size of ITA-BGePSL increased significantly to 141.2±2.3nm. At the same time, due to the positive charge of gelatin, the Zeta potential of ITA-BGePSL increased to -14.7±0.6mV. In addition, the PDI of ITA-BGePSL was 0.23±0.03, and the particle size uniformity was good.
[0065] 3. Encapsulation rate
[0066] 1 mL of sample was placed in the sample pool and balanced at 25 °C for 120 s. The operation was repeated 3 times and the average value was taken. The encapsulation efficiency of ITA-BGePSL was determined by ultrafiltration. 1 mL of ITA-BGePSL was placed in an ultrafiltration tube (MWCO = 10 kDa) and centrifuged at 4000 rpm for 30 min. 0.2 mL of the filtrate was accurately pipetted and added to isopropanol and methanol for ultrasonic dissolution. The mobile phase was constant to volume. The ITA content was determined by HPLC as W1; another 0.2 mL of ITA-BGePSL was accurately pipetted and added to isopropanol and methanol for ultrasonic dissolution. The mobile phase was constant to volume. The ITA content was determined by HPLC as W2. The encapsulation efficiency was calculated as follows: EE (%) = (1–W1 / W2) × 100%.
[0067] The liquid phase conditions for HPLC determination are: chromatographic column: Cosmosil C18 (5μm, 250mm×4.6mm); 0.02mol / L potassium dihydrogen phosphate (pH adjusted to 3.5 with phosphoric acid)-methanol (80:20); flow rate: 1mL / min; column temperature: 35℃; injection volume: 10μL; detection wavelength: 205nm.
[0068] The encapsulation efficiency of itaconic acid in the ITA-BGePSL prepared in Example 1 was 58.2±3.9%.
[0069] Example 3 Atomization and deposition test of itaconic acid lipid nano-carrier
[0070] In order to investigate the potential clinical translatability of the itaconic acid lipid nanocarriers prepared in Example 1 for intranasal delivery, the aerosolization potential of the itaconic acid lipid nanocarriers was evaluated using a nebulizer device.
[0071] BGel (gel group, obtained by the reaction of Gelatin-dopamine, BafA1 and TG enzyme), ITA-PSL (liposome group, step 3 of Example 1) and ITA-BGePSL (nano-tank group) were respectively placed in nasal spray bottles and sprayed at a distance of 15 cm (the maximum distance between the human nostril and the nasopharynx, the surface area of the human nasal cavity is about 80-160 cm 2 ) on a vertical paper ( Figure 7 ).
[0072] The spray range was visualized using black food coloring, which was then imaged and analyzed using Image J to measure the spray deposition rate, spray deposition surface area, and spray ellipticity. Ellipticity = Dmax (longer diameter) / Dmin (shorter diameter), and the absolute ellipticity value is 1, where Dmax = Dmin. The results are shown in Figure 8 As shown, from Figure 8 It can be seen that the spray areas of BGel, ITA-PSL and ITA-BGePSL are all greater than 80 cm 2 , and the spray ellipticity is close to 1, indicating that they all have good sprayability; compared with BGel, ITA-PSL and ITA-BGePSL have larger spray coverage and spray area.
[0073] According to the morphological position of the nostrils and the nasopharynx (the back of the nasal cavity), the latex tube was bent at a certain angle, and BGel (gel group), ITA-PSL (liposome group) and ITA-BGePSL (nano chamber group) were sprayed in the bent tube to investigate their retention ability in the olfactory area. Fig. 9 As shown, from Fig. 9 It can be seen that ITA-BGePSL has more deposition in the top olfactory simulation area compared with BGel and ITA-PSL. The possible reason is that although ITA-PSL has good sprayability, its retention and adhesion are weak; although BGel retains the adhesion of the gel, the spraying distance is relatively short, causing it to deposit more in areas such as the nasal vestibule; and ITA-GePSL retains the adhesion of the gel while having the spray performance of liposomes, which makes it more retained in the olfactory area.
[0074] Example 4 Investigation of the pathway of itaconic acid lipid nanocompartment entering the brain
[0075] PSL (0.1 mL) was labeled with the fluorescent dye DiI (10 mg / mL; 10 μL), and Gelatin-dopamine was labeled with FITC to prepare fluorescently labeled BGePSL (except that ITA was not loaded, the other steps were the same as those in Example 1). PC12 cells were cultured at 10×10 4 The number of nasal epithelial basal cells was 7.5×10 4Each well was inoculated into a 12-well plate and incubated at 5% CO2 and 37°C for 12 hours. The original culture medium was then discarded, and the fluorescently labeled BGePSL solution was added. After incubation for 2 hours and 12 hours, each group of cells was collected, washed once with PBS, and then resuspended by blowing in 400 μL PBS to obtain a single cell suspension. The fluorescence values of DiI-PSL and FITC-BGel in the two cells were detected by flow cytometry. Data analysis was performed using FlowJov10.8.1.
[0076] The results are as follows Fig.10 As shown, compared with nasal epithelial basal cells, at different time points, the fluorescence intensity of DiI and FITC in PC12 cells was significantly stronger, and the uptake of BGePSL by PC12 cells was time-dependent, and DiI-labeled liposomes and FITC-labeled gels showed the same uptake trend. The results showed that dopamine-modified BGePSL was selectively and highly taken up by PC12 cells through DRD2.
[0077] Example 5 Determination of drug content in exosomes converted from lipid nanocompartments
[0078] The water-soluble fluorescent dye RhB (simulating the water-soluble drug itaconic acid) was used instead of ITA, and the reverse evaporation method was used to prepare PSL loaded with RhB (this drug loading method can directly load the drug into the inner water cavity of the liposome, which better simulates the loading of water-soluble drugs), and it was used to prepare RhB-BGePSL, a lipid nanocompartment loaded with RhB.
[0079] PC12 cells were cultured at 400×10 4 100 cells / well were inoculated into a cell culture dish and cultured at 5% CO2 and 37°C for 48h. When the cell confluence reached 80%, the original culture medium was discarded and exosome-free medium containing RhB-BGePSL (64μg / mL) was added. After 2h, the drug-containing medium was discarded, and fresh exosome-free medium was added to continue culturing for 24h. The cell culture supernatant was collected and centrifuged at 500g for 1h to discard cell debris; the supernatant was collected and centrifuged at 2500g for 1h to discard apoptotic bodies; the supernatant was collected and centrifuged at 20000g for 1h to discard microcapsules; the supernatant was collected and centrifuged at 110000g for 70min to collect exosomes. Subsequently, fresh exosome-free medium was added and cultured for another 24h to collect exosomes secreted between 24h and 48h. Repeat the above operation to collect exosomes secreted between 48h and 72h.
[0080] The content of RhB in exosomes released by PC12 cells was detected by microplate reader. In addition, flow cytometry was used to measure the changes in the fluorescence value of RhB in PC12 cells after 2, 24, 48 and 72 hours.
[0081] The results are as follows Figure 11-12As shown in the figure, taking the fluorescence value of PC12 cells 2 hours after ingestion as the benchmark 100%, it can be seen that the fluorescence values of PC12 cells decreased to 57.6%, 51.8% and 40.9% at 24, 48 and 72 hours, respectively ( Fig.11 ). The fluorescence value of RhB in PC12 cell exosomes was detected, and the results showed that the content of RhB in exosomes accounted for 32.0%, 36.3% and 39.6% of the total cellular uptake at 24, 48 and 72 hours, respectively ( Fig.12 ). The above results show that 59.1% of RhB was reduced from PC12 cells at 72h, while 39.6% of RhB appeared in the exosomes released by PC12 cells, and this conversion was more efficient within the first 24h.
[0082] The results of this example indicate that the mechanism of action of the itaconic acid lipid nano-tanks of the present invention is likely that since the olfactory neurons are directly connected to the olfactory bulb of the brain, they convert the itaconic acid lipid nano-tanks into itaconic acid exosomes, which are delivered into the brain, thereby improving the efficiency of drug nose-brain delivery.
[0083] Example 6 Investigation of brain targeting of itaconic acid lipid nanocompartments
[0084] Fluorescent dye DiD was used to label gel (obtained by the reaction of Gelatin-dopamine, BafA and TG enzyme), liposomes and nanocompartments (ITA itself cannot spontaneously fluoresce, and fluorescent dye DiD was used instead of ITA for imaging and tracing) to obtain DiD-labeled BGel, PSL and BGePSL. BALB / c mice were randomly divided into 3 groups, and each group was intranasally administered with DiD-labeled BGel, PSL and BGePSL (0.25 mg / kg). After 12 hours of administration, whole-body fluorescence imaging of mice was performed using a small animal in vivo imaging system. The mice were then euthanized, and the heart, liver, spleen, lung, kidney and brain of the mice were dissected and separated, and the in vivo distribution of the drug at 630 / 680nm excitation / emission wavelengths was captured using a small animal in vivo imaging system.
[0085] The experimental results are as follows Figure 13 to Figure 17 As shown, the results showed that the BGePSL group had significantly more fluorescence distribution in the brain than the BGel group and the PSL group. The possible reason is that DiD is more easily transported by cells after being loaded into liposomes, and the modification of the nanocompartment by dopamine allows it to enter the brain more through the olfactory nerve pathway. In addition, bafilomycin A1 promotes the exocytosis of exosomes from olfactory neurons, thereby allowing more nanocompartments loaded with DiD that enter the olfactory neurons to be converted into the brain.
[0086] Experimental Example 1 Effect of the ratio of lecithin to phosphatidylserine on the particle size and polydispersity index of blank liposomes (PSL)
[0087] This test example investigated the effects of different ratios of phosphatidylcholine to phosphatidylserine on the particle size and polydispersity index (PDI) of the prepared blank liposomes (PSL).
[0088] Table 1 Effect of the ratio of lecithin to phosphatidylserine
[0089] Phosphatidylserine (mg) Particle size (nm) PDI 9:1 87.54±2.11 0.179±0.002 8:2 86.65±0.25 0.209±0.018 7:3 98.21±1.87 0.204±0.003 6:4 102.00±0.463 0.463±1.245
[0090] From the results in Table 1, it can be seen that when the ratio of lecithin to phosphatidylserine is in the range of 9:1 to 7:3, the prepared PSL has a good particle size and polydispersity index (PDI). However, when the ratio is increased to 6:4, the PDI is greater than 0.3, the particle size distribution is large, and it is unstable. Since phosphatidylserine can be used as an "Eatme" signal to enhance its uptake by targeted microglia, therefore, when the ratio of lecithin to phosphatidylserine is 7:3, the comprehensive performance is optimal.
[0091] Experimental Example 2 Investigation of the preparation process of itaconic acid-loaded phosphatidylserine liposomes
[0092] This experimental example investigated the effects of preparation processes such as the type of external aqueous phase buffer, the pH difference between the internal and external aqueous phases, the concentration of the hydration medium, the drug-lipid ratio, the incubation time, and the incubation temperature on the performance of the product during the preparation of itaconic acid-loaded phosphatidylserine liposomes (ITA-PSL).
[0093] 1. Type of external aqueous phase buffer and pH difference between internal and external aqueous phases
[0094] The pH value of the inner aqueous phase of PSL is 7.4. According to literature reports, when the difference between the inner and outer aqueous phases is greater than 3, the pH gradient method can effectively load the drug into the inner aqueous phase. This test example sets three outer aqueous phase pH values, namely 4.3, 3.3, and 2.3, and investigates the effects of different types of outer aqueous phase buffers (citric acid-sodium citrate buffer, glycine-hydrochloric acid buffer) on the encapsulation efficiency (other conditions are the same as in Example 1). The results are shown in Table 2.
[0095] Table 2 Effect of external aqueous phase buffer type and internal and external aqueous phase pH difference
[0096]
[0097] The results in Table 2 show that compared with citric acid-sodium citrate buffer, the encapsulation rate of ITA-PSL is relatively higher when glycine-hydrochloric acid buffer is used as the external aqueous phase buffer; when glycine-hydrochloric acid buffer with a pH value of 3.3 is used as the external aqueous phase, ITA-PSL has a significantly higher encapsulation rate.
[0098] 2. Ion concentration of PBS buffer in the internal aqueous phase
[0099] The ion concentration of the inner aqueous phase PBS buffer (i.e., the ion concentration of the hydration medium) is a key factor affecting the encapsulation efficiency of the pH gradient method. This test example investigated the effects of different ion concentrations of the hydration medium on the particle size and encapsulation efficiency (other conditions were the same as in Example 1), and the results are shown in Table 3.
[0100] Table 3 Effect of ion concentration of hydration medium
[0101]
[0102]
[0103] From the results in Table 3, it can be seen that, compared with other ion concentrations, when the ion concentration of the inner aqueous phase PBS buffer is 50 mM, ITA-PSL has a significantly higher encapsulation rate.
[0104] 3. Drug-to-lipid ratio
[0105] This test example investigated the effects of different drug-to-lipid ratios on particle size and encapsulation efficiency (other conditions were the same as in Example 1). The results are shown in Table 4.
[0106] Table 4 Effect of drug-to-lipid ratio
[0107] Drug-to-lipid ratio Particle size (nm) Encapsulation rate (%) 1:20 110.9±2.55 12.42±5.63 1:16.7 115.3±4.69 13.74±1.17 1:10 99.49±1.08 63.57±2.94 1:5 95.14±0.29 41.75±3.12 1:3 101.9±1.17 40.33±2.84
[0108] The results in Table 4 show that when the drug-lipid ratio is 1:10, the encapsulation efficiency of ITA-PSL is the highest, about 63.57%, which is significantly higher than the encapsulation efficiency of ITA-PSL at other drug-lipid ratios.
[0109] 4. Incubation time
[0110] This test example investigated the effect of different incubation times on the encapsulation efficiency (other conditions were the same as in Example 1), and the results are shown in Table 5.
[0111] Table 5 Effect of incubation time
[0112] Incubation time (min) Encapsulation rate (%) 5 63.57±2.94 10 52.13±1.26 20 7.22±2.33 30 29.46±2.18 40 46.34±0.05 50 32.45±1.03
[0113] The results in Table 5 show that when the incubation time is 5 to 10 min, the encapsulation efficiency of ITA-PSL is significantly higher than that of other incubation times, and the encapsulation efficiency is the highest when the incubation time is 5 min.
[0114] 5. Incubation temperature
[0115] This test example investigated the effect of different incubation temperatures on the encapsulation efficiency (other conditions were the same as in Example 1), and the results are shown in Table 6.
[0116] Table 6 Effect of incubation temperature
[0117] Incubation temperature (℃) Encapsulation rate (%) 37 42.00±1.17 50 63.57±2.94
[0118] The results in Table 6 show that when the incubation temperature is above the phase transition temperature of the phospholipid bilayer of the liposome, it can promote the shuttling of drug molecules into the inner water phase, thereby increasing the encapsulation efficiency. When the incubation temperature is 50°C, the encapsulation efficiency of ITA-PSL is significantly higher.
[0119] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A lipid nanoparticle system loaded with a water-soluble drug, characterized in that: The preparation raw materials include 3-5wt% dopamine modified gelatin, liposome loaded with water-soluble drugs, 8-12mM bafilomycin A1 and 8-12mg / mL TG enzyme; the volume ratio of the dopamine modified gelatin to the liposome loaded with water-soluble drugs is 1:2.5-3.5, and the volume ratio of the bafilomycin A1 to the TG enzyme is 1:9-11.
2. The lipid nanoparticle system loaded with water-soluble drugs according to claim 1, characterized in that: The volume ratio of the dopamine-modified gelatin to the liposome loaded with the water-soluble drug is 1:2.8-3.2, and the volume ratio of the bafilomycin A1 to the TG enzyme is 1:9.5-10.
5.
3. The lipid nanoparticle system loaded with water-soluble drugs according to claim 1 or 2, characterized in that: The liposome loaded with a water-soluble drug is prepared by the following preparation method: using lecithin, phosphatidylserine and cholesterol as raw materials, and using a PBS buffer solution with a pH of 7.4 and an ion concentration of 45 to 55 mM as a medium to prepare blank liposomes; dissolving the water-soluble drug in a glycine-hydrochloric acid buffer solution with a pH of 3.2 to 4.4, and adding the drug to the blank liposome at a drug-lipid ratio of 1:3 to 10, incubating at 37 to 50° C. under magnetic stirring for 4 to 12 minutes, and gently shaking in a cold water bath to cool down, thereby obtaining the liposome.
4. The lipid nanoparticle system loaded with water-soluble drugs according to claim 3, characterized in that: The ion concentration of the PBS buffer is 49-51 mM.
5. The lipid nanoparticle system loaded with water-soluble drugs according to claim 3, characterized in that: The weight ratio of the lecithin to phosphatidylserine is 7-9:1-3, and the weight ratio of the lecithin to phosphatidylserine and cholesterol is 3:0.8-1.2; preferably, the weight ratio of the lecithin to phosphatidylserine is 7:3 or 8:2, more preferably 7:
3.
6. The lipid nanoparticle system loaded with water-soluble drugs according to claim 3, characterized in that: The pH of the glycine-hydrochloric acid buffer is 3.2-3.4, more preferably 3.3; and / or the drug-lipid ratio is 1:9-10, more preferably 1:
10.
7. The lipid nanoparticle system loaded with water-soluble drugs according to claim 3, characterized in that: The incubation temperature is 45-50° C., more preferably 50° C.; and / or the incubation time is 4-6 min, more preferably 5 min.
8. The lipid nanoparticle system loaded with a water-soluble drug according to any one of claims 1 to 7, characterized in that: The water-soluble drug is itaconic acid, mesaconic acid or citraconic acid.
9. The method for preparing the lipid nanoparticle system loaded with water-soluble drugs according to any one of claims 1 to 8, characterized in that: The following steps are involved: The method comprises adding 8-12 mM bafilomycin A1 to 3-5 wt % dopamine modified gelatin, and then adding liposomes loaded with water-soluble drugs and 8-12 mg / mL TG enzyme, and incubating at room temperature for 1.5-2.5 hours to obtain the product.
10. Use of the lipid nanoparticle system loaded with a water-soluble drug according to any one of claims 1 to 8 in drug delivery via the nose-brain pathway.
Citation Information
Patent Citations
Liquid-state lipid micro-particles used for delivering cerebric medicine through olfactory pathway, preparation method thereof, and preparation thereof
CN102370623A
Targeted intestinal epithelial cell pyroptosis inhibitor drug delivery system and preparation method and application thereof
CN118105524A
IN957MU2013A
Cited By
Preparation method and application of exosome vesicles capable of efficiently loading drugs
CN120168653A
